Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

• Conditions: Hepatitis c

• Registration Number: NCT03591783
• Lead Sponsor: Assiut University

Brief Summary

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highest prevalence of HCV infection worldwide exists in Egypt (15%); 90% of infection among Egyptian patients is due to genotype 4

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-07
• Study First Submitted: 2018-07-09
• Study First Submitted QC: 2018-07-09
• Last Update Submitted: 2018-07-09
• Study First Posted: 2018-07-19
• Last Update Posted: 2018-07-19
• Study Start: 2018-08
• Primary Completion: 2019-11
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• Chronic HCV infection will be diagnosed based on positive testing for serum HCV RNA and anti-HCV Ab.
• Diagnosis of type 2 DM will depend on fasting level of serum glucose more than 126 mg/dl and/or serum level of HbA1c more than 6.5 % on oral hypoglycemic therapy.

Read More

Exclusion Criteria

• Chronic hepatitis due to causes other than HCV infection
• Coinfection with HBV infection
• Hepatocellular carcinoma
• Child C stage of liver cirrhosis.
• Patients with type I diabetes mellitus.
• Cardiopulmonary diseases.
• Major illness.
• Patient receiving corticosteroids.
• Patient refused consent.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the percentage of patients with glycemic control	3 months	Exploring the impact of achieving SVR by directly acting antiviral drugs on glycemic control among diabetic patients with HCV infection.